ixekizumab sold brand name taltz injectable medication treatment autoimmune diseases chemically form humanized monoclonal substance acts binding interleukin neutralizing reducing common side effects include upper respiratory infections injection site reactions fungal tinea drug developed eli lilly co approved treatment plaque psoriasis european union united states united states ixekizumab indicated treatment adults moderatetosevere plaque psoriasis candidates systemic therapy phototherapy active psoriatic arthritis active ankylosing spondylitis active nonradiographic axial spondyloarthritis objective signs european union indicated treatment moderatetosevere plaque secondline therapy active psoriatic studies drug reduced psoriasis area severity index least patients first three months treatment depending dosing scheme patients experienced complete absence psoriasis symptoms placebo group reached patients none group patients receiving etanercept older antipsoriasis drug reached study week ixekizumab treated patients relapsed depending dosing scheme compared medication contraindicated patients certain infections active studies ixekizumab increased rate infections ixekizumab treated patients compared placebo including severe ones versus placebo common side effects included injection site reactions redness pain versus oropharyngeal pain nausea fourfold doses given studies without causing serious side interaction studies done ixekizumab interleukin known interact cytochrome cyp liver enzymes since inflammation suppresses cyp activity theorized ixekizumab could neutralize effect lower blood plasma concentrations drugs metabolized cyp enzymes ixekizumab binds interleukin proinflammatory cytokine blocks action among things stimulates proliferation activation keratinocytes mechanism similar another antipsoriasis antibody brodalumab binds antibody affinity homodimer heterodimer members interleukin subcutaneous injection ixekizumab bioavailability highest blood plasma concentrations reached four seven days single dose usual dosing scheme loading plus dose every two weeks steady state concentrations reached eighth week like antibodies ixekizumab probably degraded proteolysis elimination halflife ixekizumab complete monoclonal antibody subclass consisting two light chains two heavy chains linked disulfide bridges heavy chains glycosylated asparagine position hinge region serine replaced proline reduce formation halfantibodies heterodimers manufacturing process terminal lysine found wildtype removed antibody produced chinese hamster ovary clinical trials included phase ii trial patients moderate severe phase iii openlabel citation needed ixekizumab approved us food drug administration fda march treatment adults moderatetosevere plaque european medicines agency ema april safety efficacy ixekizumab established three randomized placebocontrolled clinical trials total participants plaque psoriasis candidates systemic phototherapy fda approved ixekizumab based evidence three clinical trials participants moderate severe trials conducted us canada europe russia mexico chile argentina japan december fda approved active psoriatic immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiixekizumab